News and Announcements
Bioactive Laboratories – On Target For a US Launch Within 24 Months
- Published December 16, 2015 12:22PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Enormous growth has occurred in 2015. Bioactive has brought forward its drug development pipeline by two years after significant infectious disease discoveries were confirmed by the Walter and Eliza Hall Institute of Medical Research. Collaboration and the formation of a new pharmaceutical company have resulted.
On the back of these discoveries Managing Director Rick Ferdinands was invited by Trade Minister Andrew Robb to attend a tropical medicine event where the company is now discussing funding and commercial opportunities with global philanthropic and pharmaceutical companies.
Furthermore, Bioactive’s flagship ‘stomach friendly’ anti-inflammatory is on target for a US launch of its arthritis supplement within 24 months.
With an investor offer open click here to view the latest Wholesale Investor presentation.
ABOUT BIOACTIVE LABORATORIES
Bioactive Laboratories specialises in plant based enhanced extracts. They have developed an anti-microbial that is potent to one of the worlds most deadly & widespread pathogens affecting over 200m people globally in 2012. The magnitude of this discovery has not been seen since the early 1970’s in a plant based treatment for a major infectious disease.
Consequently, Bioactive have forged a collaboration agreement and formed a new pharmaceutical company with the Walter and Eliza Hall institute of Medical Research (WEHI). Financial returns are estimated within 24 months. In addition, Bioactive is steaming ahead with its anti-inflammatory and pain relieving agent that is gentle to the stomach. A US market entry is planned within the next 12 to 18 months, focussing on the US$1.6billion arthritis supplement market.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
